- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Clinical Updates in Psoriatic Arthritis
The Rheumatology Network psoriatic arthritis clinical focus page provides information on the latest psoriatic arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for psoriatic arthritis drugs.
Long-term Data Suggests Deucravacitinib Safe, Effective for Treating Plaque Psoriasis
May 12, 2022
Data from the POETYK PSO long-term extension (LTE) trial showed deucravacitinib was clinically effective and safe for treating adult patients with moderate-to-severe plaque psoriasis.
Ustekinumab, TNFi Show Similar Persistence at 1 Year in Real-World PsA Study
May 09, 2022
One-year results from the PsABio study provide evidence on factors that may impact treatment selection and decisions in clinical practice.
Guselkumab Decreases Levels of Collagen-Degrading Biomarkers in Patients With PsA
May 04, 2022
“Biomarkers can be used to elucidate normal and pathological processes and to measure biological response to a therapeutic intervention,” investigators stated.
Q&A: Long-Term Safety of Ixekizumab Use in Patients With Psoriatic Arthritis
May 02, 2022
In this Q&A, Gerd R. Burmester, MD, discussed the findings of his study that evaluated the exposure to ixekizumab, outcomes and medical history of patients with active psoriatic arthritis (PsA) who experienced adverse events.
Jeffrey Stark, MD: Latest Bimekizumab Data for Treatment of Psoriatic Arthritis, Psoriasis
April 26, 2022
Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.
Secukinumab Improves Disease Activity in Patients With PsA, axSpA
April 25, 2022
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
Treatment With bDMARDs Improves Quality of Life in Patients With PsA
April 20, 2022
As quality of life (QoL) in patients with psoriatic arthritis (PsA) is significantly lower when compared with patients with psoriasis, one of the main goals of treating PsA is improving QoL.
Males With Psoriatic Arthritis Receiving Ixekizumab Reported Better Outcomes; Response Rates
April 15, 2022
Understanding the differences between sexes regarding PsA treatment may change the management of PsA in male and female patients and improve outcomes.
Poor Treatment Response Linked to Residual Disease in Patients with PsA
April 14, 2022
“Although the achievement of treatment targets has been associated with improved quality of life and slower disease progression, patients may still experience symptoms and a burden of disease,” investigators stated.
Dietary Changes May Improve PsA Symptoms
April 12, 2022
Dietary counseling could play an important role in the treatment of patients with psoriatic arthritis, contributing to better disease activity control.